The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Triple-negative myelofibrosis: disease features and outcomes
Rami Komrokji, MD, Moffitt Cancer Center, Tampa, FL, discusses a recent publication exploring the disease features, response to treatment, and outcomes of patients with triple-negative myelofibrosis (TN-MF). TN-MF is characterized by a lack of mutations in the JAK2, MPL, and CALR genes. This subset of patients makes up around 10% of all patients with MF, with TN-MF being associated with a poorer prognosis. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
